To verify the function of GLRX3 in pancreatic cancer tumorigenicity in vivo, we injected GLRX3 knockdown or control cells subcutaneously into SCID mice and measured the resulting tumor growth after 14 weeks (Fig. 3E). The gene discussed is GLRX3; the disease is familial pancreatic carcinoma.